Solventum saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 74 to 85.
Hone Your Stock-Picking Skills By Focusing On These Factors
This unique rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of other stocks on the major indexes.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating of over 80 as they launch their biggest runs.
Solventum is trying to complete a consolidation with an 85.92 buy point. See if it can break out in volume at least 40% above average.
Earnings growth fell in the most recent quarter from -35% to -36%. But revenue moved higher, from 2% to 3%.
Solventum holds the No. 28 rank among its peers in the Medical-Products industry group. Penumbra, Boston Scientific and Insulet are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
